Host: Timothy Fenske, MD, MS The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US

Host: Timothy Fenske, MD, MS The anti-CD20 antibody rituximab has been the backbone of initial treatment for previously untreated follicular lymphoma (FL). The treatment options for FL are expanding, with multiple novel agents now approved by the US

Host: Ruben A. Mesa, MD, FACP The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand

Host: Ruben A. Mesa, MD, FACP The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand

Host: Robert Mocharnuk, MD Guest: Richard S. Finn, MD Guest: Amit Singal, MD, MS The majority of patients with HCC have advanced disease at diagnosis and aren’t candidates for potentially curative treatment options, such as resection, liver trans

Host: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Guest: Raymond Chung, MD Guest: Douglas Dieterich, MD, FACP Health care providers need to use effective strategies to enhance adherence to CHB treatment and retain patients in care by providing inform

Host: Jennifer Caudle, DO Guest: Koryn Rubin With the widespread impacts of the COVID-19 pandemic, the Centers for Medicare and Medicaid Services is now offering flexibility for clinicians participating in the Merit-Based Incentive Payment System,

Host: Kevin Brown, MD Guest: Kevin R. Flaherty, MD Guest: Rebecca C. Keith, MD Chronic Fibrosing ILD with a Progressive Lung Disease Phenotype (PF-ILD) occurs in multiple, overlapping clinical settings, and differentiating them can be frustrating

Guest: Karen Reckamp, MS, MD Guest: Heather Wakelee, MD Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscap

Host: Karen Reckamp, MS, MD Host: Heather Wakelee, MD Because of advances in the understanding of molecular-driven pathways in non–small cell lung cancer (NSCLC) and the availability of targeted therapies and immunotherapy, the treatment landscape